CGM for Type 2 Diabetes: Why the Rules Just Changed
- t2diabetesnetwork
- 2 days ago
- 4 min read
Written by Clare Koning, RN, PhD
T2D Network | April 2026 | 5 min read
Key Highlights
✅ The 2026 ADA Standards of Care now recommend CGM for people with T2D, even those not on insulin
✅ Real-world evidence shows CGM reduces HbA1c by 0.6%–0.9% and cuts diabetes-related hospitalizations by up to 67%
✅ CGM helps you understand how food, exercise, and stress affect your glucose in real time
✅ Over-the-counter CGM options now make this technology more accessible than ever
✅ Talk to your care team, coverage and eligibility criteria in Canada are evolving
For most of the history of continuous glucose monitoring (CGM), the technology was primarily associated with Type 1 diabetes and people on intensive insulin therapy. If you had Type 2 diabetes and weren't on insulin, a CGM was seen as a "nice to have", not a clinical priority.
That's changed in 2026.
The American Diabetes Association's updated Standards of Care, the most widely referenced clinical guidelines in diabetes, now recommend CGM from the time of diagnosis and at any point thereafter, including for people with type 2 diabetes who are on non-insulin therapies. This marks a significant shift, and it has real implications for how you and your care team might approach your diabetes management.
Here's what you need to know.
What Is a CGM?
A continuous glucose monitor is a small wearable sensor, typically worn on the arm or abdomen, that measures glucose levels in the fluid just beneath the skin and transmits readings to your smartphone or a small receiver, usually every few minutes, around the clock.
Unlike traditional fingerstick testing, which gives you a snapshot at one moment, a CGM gives you a continuous picture: you can see whether your glucose is rising, falling, or stable, how quickly it's changing, and how it responds to specific foods, physical activity, stress, or sleep.
Why Does This Matter for T2D?
Most people with type 2 diabetes don't use insulin, and historically, that meant many weren't considered candidates for CGM. But the benefits of real-time glucose feedback go beyond just informing insulin dosing.
The evidence for CGM in non-insulin-using T2D has been building steadily:
A real-world study published in Scientific Reports found that CGM use in primary care patients with T2D on non-insulin or basal insulin therapy was associated with a significant HbA1c reduction of 0.62% at three months, along with meaningful improvements in time-in-range (from 39.7% to 61.9%) and reductions in time spent at elevated glucose levels.
A large retrospective study using Aetna insurance data found that after starting CGM, people with diabetes — including T2D patients not on insulin — showed an average A1c improvement of 0.9%, alongside a 67% reduction in diabetes-related hospitalizations and a 40% drop in emergency department visits.
A meta-analysis published in Diabetologia confirmed a consistent, modest reduction in HbA1c across people with T2D regardless of whether they were on insulin, together with a 6.4% improvement in time in range.
These are clinically meaningful numbers. And beyond the blood sugar metrics, CGM data gives people insight into their own patterns — showing, for instance, that a particular food causes a glucose spike, or that a 20-minute walk after dinner makes a real difference. That kind of real-time, personalized feedback is hard to replicate with periodic fingerstick measurements.
As the 2026 ADA Standards note, the benefits of CGM have been shown regardless of age, sex, education, income level, or baseline diabetes characteristics.
What's Changed in the 2026 Guidelines?
The 2026 ADA Standards of Care made two particularly notable updates:
CGM is now recommended at diabetes onset, not just after a patient has been struggling to reach glycemic targets.
The recommendation now explicitly includes people with T2D on non-insulin therapies, not just a soft "consider" but a genuine recommendation when CGM would aid management.
The guidelines also removed intermittently scanned CGM from the list of recognized current technologies, reinforcing real-time CGM (rtCGM) as the standard of care. Real-time systems continuously transmit data and can alert you to dangerous highs or lows proactively, a meaningful safety advantage over systems that only record data when you scan them.
What Are the Options?
CGM devices have expanded considerably in recent years:
Dexcom G7: widely available, 10-day wear, known for accuracy and real-time alerts
Abbott FreeStyle Libre 3 Plus: one of the most widely used globally, compatible with automated insulin delivery systems
Eversense 365: an implantable CGM with a one-year sensor life, for those seeking minimal day-to-day device management
Some CGMs are now available over-the-counter (OTC) in the U.S. without a prescription, dramatically lowering the access barrier. Canadian availability and coverage criteria are evolving, check with your pharmacist or diabetes care team for the most current information.
What Should You Ask Your Care Team?
If you're managing type 2 diabetes and haven't tried a CGM, these are worth raising at your next appointment:
Am I eligible for CGM coverage through my provincial drug plan, extended benefits, or diabetes education program?
Would CGM help me understand a specific pattern, like post meal spikes, overnight trends, or the impact of exercise?
Which device would work best for my lifestyle?
Do I need training? Most diabetes education centres and primary care networks can walk you through setup and interpretation.
The technology is not a replacement for your medications, healthy eating, or physical activity. But as a real-time mirror for your metabolic health, it can be a remarkably powerful complement, giving you and your care team better information to make better decisions.
Interested in learning more about monitoring and technology? Visit the T2D Network's Monitoring & Medication page.